Guest: Sara Tolaney MD, MPH <br>


  <p>What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting. </p>

Guest: Sara Tolaney MD, MPH What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting.

Emerging Roles for Immunotherapy in HER2+ Breast Cancer

Advances in Women’s Health addresses advances, breakthroughs, and treatments for conditions related to women’s health, as well as preventive measures physicians can advise their patients to pursue. Topics will include breast health as it relates to cancer, ethnicity, fertility, and pregnancy; osteoporosis; female athletes’ health and emotional issues; mental health; pregnancy and all facets related to it; aging; nutrition and health; eating disorders; alternative medicine; and sex education.

Share Emerging Roles for Immunotherapy in HER2+ Breast Cancer

Sign up to save your podcasts

Emerging Roles for Immunotherapy in HER2+ Breast Cancer

Emerging Roles for Immunotherapy in HER2+ Breast Cancer

More shows like Advances in Women's Health

Medical Industry Feature

SexMed

Partners in Practice

Second Opinion LIVE!

Medical Breakthroughs from Penn Medicine

GI Insights

Conference Coverage

HOT For Your Health

Up First from NPR

You Are Not Broken

Dr. Streicher’s Inside Information: Menopause, Midlife, and More